London 2014 Registration Visa Letters Programme Satellite Meetings Glaucoma Day 2014 Exhibition Hotel Booking Virtual Exhibition Star Alliance
london escrs

Course handouts are now available
Click here


Come to London

video-icon

WATCH to find out why


Site updates:

Programme Updates. Programme Overview and - Video Symposium on Challenging Cases now available.


Posters

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Ranibizumab for the complex treatment of neovascular glaucoma in patients with proliferative diabetic retinopathy

Poster Details

First Author: T.Zimina UKRAINE

Co Author(s):    I. Pastukh   A. Mezentseva           

Abstract Details



Purpose:

To present and analyze results of intravitreal (IVT) ranibizumab (Lucentis) for the complex treatment of neovascular glaucoma (NG) in patients with proliferative diabetic retinopathy (PDR)

Setting:

Kharkiv City Clinical Hospital № 14 named after prof. L.L. Girshman, Ukraine; Ophthalmology Department, Kharkov Medical Academy of Postgraduate Education, Ukraine

Methods:

Two adult patients (3 eyes) with NG and PDR were assigned to receive 2 monthly IVT injections of 0.5 mg ranibizumab. 1 week after first injection Trabeculectomy was performed and intraocular pressure (IOP) decreased. 1 week after second injection Phacoemulsification with intraocular lens (IOL) implantation was performed. After 3-4 weeks retinal laser coagulation performed for all eyes. Assessment of visual acuity changes was the percentage of patients gaining of best-corrected visual acuity (BCVA); the central retinal thickness (CRT) measured by optical coherence tomography (OCT); tonometry, biomicroscopy, fundus photographs, and fluorescein angiography were evaluated.

Results:

1 week after first IVT ranibizumab injection iris neovascularisation decreased and Trabeculectomy was performed. IOP become 15-16 mm Hg. 1 week after second ranibizumab injection Phacoemulsification with intraocular lens (IOL) implantation was performed. After 2 months of follow-up all patients gained BCVA; mean BCVA improved on 10-15%. CRT showed a mean decrease of 45-55%. IOP was normal. These gave opportunity to start retinal laser coagulation for all eyes. After 6 and 12 months of follow-up BCVA and IOP remained steady. Term of observation is one year.

Conclusions:

Ranibizumab is generally well-tolerated in complex treatment of neovascular glaucoma in patients with proliferative diabetic retinopathy. It gives opportunity to decrease iris neovascularisation, CRT, and perform surgery with retinal laser coagulation. FINANCIAL INTEREST: NONE

Back to Poster listing